Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for Aromatase Inhibitor-Associated Musculoskeletal Syndrome
NCT07825454Phase 2Not yet recruiting
- Sponsor
- Indiana University
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS), sponsored by Indiana University. Primary endpoint: Efficacy of hydroxychloroquine at Week 12. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS)
Beyond the preview
Go deeper on NCT07825454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07825454.